nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—CYP3A4—Temozolomide—melanoma	0.188	0.576	CbGbCtD
Alfuzosin—CYP3A4—Vemurafenib—melanoma	0.103	0.316	CbGbCtD
Alfuzosin—CYP3A4—Docetaxel—melanoma	0.0354	0.108	CbGbCtD
Alfuzosin—Atrial fibrillation—Vemurafenib—melanoma	0.00685	0.0154	CcSEcCtD
Alfuzosin—Arthritis—Vemurafenib—melanoma	0.00668	0.015	CcSEcCtD
Alfuzosin—Influenza-like symptoms—Temozolomide—melanoma	0.0064	0.0144	CcSEcCtD
Alfuzosin—Cholestasis—Temozolomide—melanoma	0.00602	0.0135	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.00585	0.0131	CcSEcCtD
Alfuzosin—Liver injury—Temozolomide—melanoma	0.00543	0.0122	CcSEcCtD
Alfuzosin—Infestation NOS—Vemurafenib—melanoma	0.005	0.0112	CcSEcCtD
Alfuzosin—Infestation—Vemurafenib—melanoma	0.005	0.0112	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Vemurafenib—melanoma	0.0049	0.011	CcSEcCtD
Alfuzosin—Neuropathy—Carmustine—melanoma	0.00444	0.00998	CcSEcCtD
Alfuzosin—Influenza like illness—Temozolomide—melanoma	0.00444	0.00998	CcSEcCtD
Alfuzosin—Connective tissue disorder—Vemurafenib—melanoma	0.00441	0.00992	CcSEcCtD
Alfuzosin—Neuralgia—Docetaxel—melanoma	0.00438	0.00983	CcSEcCtD
Alfuzosin—Neuropathy—Temozolomide—melanoma	0.00429	0.00964	CcSEcCtD
Alfuzosin—Injury—Bleomycin—melanoma	0.00428	0.00962	CcSEcCtD
Alfuzosin—Eye disorder—Vemurafenib—melanoma	0.0042	0.00943	CcSEcCtD
Alfuzosin—Cardiac disorder—Vemurafenib—melanoma	0.00417	0.00937	CcSEcCtD
Alfuzosin—Angiopathy—Vemurafenib—melanoma	0.00408	0.00916	CcSEcCtD
Alfuzosin—Mediastinal disorder—Vemurafenib—melanoma	0.00405	0.0091	CcSEcCtD
Alfuzosin—Arthritis—Bleomycin—melanoma	0.00405	0.00909	CcSEcCtD
Alfuzosin—Back pain—Vemurafenib—melanoma	0.00378	0.0085	CcSEcCtD
Alfuzosin—Injury—Carmustine—melanoma	0.00374	0.00839	CcSEcCtD
Alfuzosin—Arthralgia—Vemurafenib—melanoma	0.00333	0.00748	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00331	0.00743	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.0033	0.00742	CcSEcCtD
Alfuzosin—Infection—Vemurafenib—melanoma	0.00317	0.00712	CcSEcCtD
Alfuzosin—Nervous system disorder—Vemurafenib—melanoma	0.00313	0.00703	CcSEcCtD
Alfuzosin—Skin disorder—Vemurafenib—melanoma	0.0031	0.00696	CcSEcCtD
Alfuzosin—Hepatocellular injury—Docetaxel—melanoma	0.00304	0.00683	CcSEcCtD
Alfuzosin—Breast disorder—Temozolomide—melanoma	0.003	0.00674	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Temozolomide—melanoma	0.00299	0.00671	CcSEcCtD
Alfuzosin—Hypotension—Vemurafenib—melanoma	0.00298	0.0067	CcSEcCtD
Alfuzosin—Influenza like illness—Docetaxel—melanoma	0.00295	0.00663	CcSEcCtD
Alfuzosin—Terazosin—ABCB1—melanoma	0.00292	0.412	CrCbGaD
Alfuzosin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00291	0.00653	CcSEcCtD
Alfuzosin—Neuropathy—Docetaxel—melanoma	0.00285	0.00641	CcSEcCtD
Alfuzosin—Bronchitis—Temozolomide—melanoma	0.00276	0.0062	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Vemurafenib—melanoma	0.00276	0.00619	CcSEcCtD
Alfuzosin—Fatigue—Vemurafenib—melanoma	0.00275	0.00618	CcSEcCtD
Alfuzosin—Constipation—Vemurafenib—melanoma	0.00273	0.00613	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Temozolomide—melanoma	0.00267	0.00599	CcSEcCtD
Alfuzosin—Erectile dysfunction—Temozolomide—melanoma	0.00264	0.00594	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Carmustine—melanoma	0.00259	0.00583	CcSEcCtD
Alfuzosin—Infestation NOS—Temozolomide—melanoma	0.00256	0.00575	CcSEcCtD
Alfuzosin—Infestation—Temozolomide—melanoma	0.00256	0.00575	CcSEcCtD
Alfuzosin—Flushing—Bleomycin—melanoma	0.00253	0.00568	CcSEcCtD
Alfuzosin—Pharyngitis—Dactinomycin—melanoma	0.00252	0.00566	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Temozolomide—melanoma	0.00251	0.00563	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Temozolomide—melanoma	0.00242	0.00543	CcSEcCtD
Alfuzosin—Sinusitis—Temozolomide—melanoma	0.0024	0.00539	CcSEcCtD
Alfuzosin—Flushing—Dactinomycin—melanoma	0.00236	0.00529	CcSEcCtD
Alfuzosin—Connective tissue disorder—Carmustine—melanoma	0.00233	0.00525	CcSEcCtD
Alfuzosin—Atrial fibrillation—Docetaxel—melanoma	0.00233	0.00523	CcSEcCtD
Alfuzosin—Asthenia—Vemurafenib—melanoma	0.00229	0.00514	CcSEcCtD
Alfuzosin—Pharyngitis—Temozolomide—melanoma	0.00228	0.00512	CcSEcCtD
Alfuzosin—Urinary tract disorder—Temozolomide—melanoma	0.00227	0.00509	CcSEcCtD
Alfuzosin—Pruritus—Vemurafenib—melanoma	0.00226	0.00507	CcSEcCtD
Alfuzosin—Connective tissue disorder—Temozolomide—melanoma	0.00226	0.00507	CcSEcCtD
Alfuzosin—Urethral disorder—Temozolomide—melanoma	0.00225	0.00506	CcSEcCtD
Alfuzosin—Eye disorder—Carmustine—melanoma	0.00222	0.00499	CcSEcCtD
Alfuzosin—Flushing—Carmustine—melanoma	0.0022	0.00495	CcSEcCtD
Alfuzosin—Ill-defined disorder—Bleomycin—melanoma	0.0022	0.00494	CcSEcCtD
Alfuzosin—Diarrhoea—Vemurafenib—melanoma	0.00218	0.00491	CcSEcCtD
Alfuzosin—Doxazosin—ABCB1—melanoma	0.00217	0.306	CrCbGaD
Alfuzosin—Eye disorder—Temozolomide—melanoma	0.00215	0.00482	CcSEcCtD
Alfuzosin—Malaise—Bleomycin—melanoma	0.00214	0.0048	CcSEcCtD
Alfuzosin—Flushing—Temozolomide—melanoma	0.00213	0.00479	CcSEcCtD
Alfuzosin—Cardiac disorder—Temozolomide—melanoma	0.00213	0.00479	CcSEcCtD
Alfuzosin—Dizziness—Vemurafenib—melanoma	0.00211	0.00474	CcSEcCtD
Alfuzosin—Angiopathy—Temozolomide—melanoma	0.00208	0.00468	CcSEcCtD
Alfuzosin—Mental disorder—Carmustine—melanoma	0.00208	0.00468	CcSEcCtD
Alfuzosin—Mediastinal disorder—Temozolomide—melanoma	0.00207	0.00465	CcSEcCtD
Alfuzosin—Ill-defined disorder—Dactinomycin—melanoma	0.00205	0.00461	CcSEcCtD
Alfuzosin—Vomiting—Vemurafenib—melanoma	0.00203	0.00456	CcSEcCtD
Alfuzosin—Chest pain—Bleomycin—melanoma	0.00202	0.00453	CcSEcCtD
Alfuzosin—Orthostatic hypotension—Docetaxel—melanoma	0.00202	0.00453	CcSEcCtD
Alfuzosin—Abdominal pain upper—Docetaxel—melanoma	0.00202	0.00453	CcSEcCtD
Alfuzosin—Rash—Vemurafenib—melanoma	0.00201	0.00452	CcSEcCtD
Alfuzosin—Mental disorder—Temozolomide—melanoma	0.00201	0.00452	CcSEcCtD
Alfuzosin—Dermatitis—Vemurafenib—melanoma	0.00201	0.00452	CcSEcCtD
Alfuzosin—Back pain—Carmustine—melanoma	0.002	0.00449	CcSEcCtD
Alfuzosin—Headache—Vemurafenib—melanoma	0.002	0.00449	CcSEcCtD
Alfuzosin—Prazosin—ABCB1—melanoma	0.002	0.282	CrCbGaD
Alfuzosin—Breast disorder—Docetaxel—melanoma	0.00199	0.00448	CcSEcCtD
Alfuzosin—Discomfort—Bleomycin—melanoma	0.00199	0.00448	CcSEcCtD
Alfuzosin—Malaise—Dactinomycin—melanoma	0.00199	0.00448	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Docetaxel—melanoma	0.00199	0.00447	CcSEcCtD
Alfuzosin—Oedema—Bleomycin—melanoma	0.00193	0.00434	CcSEcCtD
Alfuzosin—Back pain—Temozolomide—melanoma	0.00193	0.00434	CcSEcCtD
Alfuzosin—Infection—Bleomycin—melanoma	0.00192	0.00432	CcSEcCtD
Alfuzosin—Nausea—Vemurafenib—melanoma	0.0019	0.00426	CcSEcCtD
Alfuzosin—Thrombocytopenia—Bleomycin—melanoma	0.00189	0.00425	CcSEcCtD
Alfuzosin—Discomfort—Dactinomycin—melanoma	0.00186	0.00418	CcSEcCtD
Alfuzosin—Angina pectoris—Docetaxel—melanoma	0.00186	0.00417	CcSEcCtD
Alfuzosin—Ill-defined disorder—Temozolomide—melanoma	0.00185	0.00417	CcSEcCtD
Alfuzosin—Angioedema—Temozolomide—melanoma	0.00183	0.0041	CcSEcCtD
Alfuzosin—Hypotension—Bleomycin—melanoma	0.00181	0.00406	CcSEcCtD
Alfuzosin—Oedema—Dactinomycin—melanoma	0.0018	0.00405	CcSEcCtD
Alfuzosin—Malaise—Temozolomide—melanoma	0.0018	0.00405	CcSEcCtD
Alfuzosin—Vertigo—Temozolomide—melanoma	0.0018	0.00403	CcSEcCtD
Alfuzosin—Infection—Dactinomycin—melanoma	0.00179	0.00403	CcSEcCtD
Alfuzosin—Palpitations—Temozolomide—melanoma	0.00177	0.00397	CcSEcCtD
Alfuzosin—Thrombocytopenia—Dactinomycin—melanoma	0.00177	0.00397	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Bleomycin—melanoma	0.00176	0.00396	CcSEcCtD
Alfuzosin—Chest pain—Carmustine—melanoma	0.00176	0.00396	CcSEcCtD
Alfuzosin—Arthralgia—Temozolomide—melanoma	0.0017	0.00382	CcSEcCtD
Alfuzosin—Infestation NOS—Docetaxel—melanoma	0.0017	0.00382	CcSEcCtD
Alfuzosin—Infestation—Docetaxel—melanoma	0.0017	0.00382	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00169	0.0038	CcSEcCtD
Alfuzosin—Oedema—Carmustine—melanoma	0.00169	0.00379	CcSEcCtD
Alfuzosin—Discomfort—Temozolomide—melanoma	0.00168	0.00378	CcSEcCtD
Alfuzosin—Infection—Carmustine—melanoma	0.00168	0.00377	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Docetaxel—melanoma	0.00167	0.00375	CcSEcCtD
Alfuzosin—Dry mouth—Temozolomide—melanoma	0.00166	0.00374	CcSEcCtD
Alfuzosin—Jaundice—Docetaxel—melanoma	0.00166	0.00372	CcSEcCtD
Alfuzosin—Pain—Bleomycin—melanoma	0.00165	0.00372	CcSEcCtD
Alfuzosin—Thrombocytopenia—Carmustine—melanoma	0.00165	0.00371	CcSEcCtD
Alfuzosin—Tachycardia—Carmustine—melanoma	0.00165	0.0037	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00164	0.00369	CcSEcCtD
Alfuzosin—Oedema—Temozolomide—melanoma	0.00163	0.00366	CcSEcCtD
Alfuzosin—Infection—Temozolomide—melanoma	0.00162	0.00364	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Docetaxel—melanoma	0.00161	0.00361	CcSEcCtD
Alfuzosin—Nervous system disorder—Temozolomide—melanoma	0.0016	0.00359	CcSEcCtD
Alfuzosin—Thrombocytopenia—Temozolomide—melanoma	0.0016	0.00359	CcSEcCtD
Alfuzosin—Feeling abnormal—Bleomycin—melanoma	0.00159	0.00358	CcSEcCtD
Alfuzosin—Skin disorder—Temozolomide—melanoma	0.00158	0.00356	CcSEcCtD
Alfuzosin—Hypotension—Carmustine—melanoma	0.00158	0.00354	CcSEcCtD
Alfuzosin—Hyperhidrosis—Temozolomide—melanoma	0.00158	0.00354	CcSEcCtD
Alfuzosin—Fatigue—Dactinomycin—melanoma	0.00155	0.00349	CcSEcCtD
Alfuzosin—Pain—Dactinomycin—melanoma	0.00154	0.00346	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Carmustine—melanoma	0.00154	0.00345	CcSEcCtD
Alfuzosin—Urticaria—Bleomycin—melanoma	0.00154	0.00345	CcSEcCtD
Alfuzosin—Rhinitis—Docetaxel—melanoma	0.00153	0.00344	CcSEcCtD
Alfuzosin—Pharyngitis—Docetaxel—melanoma	0.00152	0.0034	CcSEcCtD
Alfuzosin—Urinary tract disorder—Docetaxel—melanoma	0.00151	0.00339	CcSEcCtD
Alfuzosin—Somnolence—Carmustine—melanoma	0.0015	0.00337	CcSEcCtD
Alfuzosin—Connective tissue disorder—Docetaxel—melanoma	0.0015	0.00337	CcSEcCtD
Alfuzosin—Urethral disorder—Docetaxel—melanoma	0.0015	0.00336	CcSEcCtD
Alfuzosin—Feeling abnormal—Dactinomycin—melanoma	0.00149	0.00334	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Temozolomide—melanoma	0.00149	0.00334	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Dactinomycin—melanoma	0.00147	0.00331	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Carmustine—melanoma	0.00146	0.00327	CcSEcCtD
Alfuzosin—Somnolence—Temozolomide—melanoma	0.00145	0.00326	CcSEcCtD
Alfuzosin—Constipation—Carmustine—melanoma	0.00144	0.00324	CcSEcCtD
Alfuzosin—Pain—Carmustine—melanoma	0.00144	0.00324	CcSEcCtD
Alfuzosin—Dyspepsia—Temozolomide—melanoma	0.00144	0.00323	CcSEcCtD
Alfuzosin—Eye disorder—Docetaxel—melanoma	0.00143	0.00321	CcSEcCtD
Alfuzosin—Abdominal pain—Dactinomycin—melanoma	0.00143	0.0032	CcSEcCtD
Alfuzosin—Cardiac disorder—Docetaxel—melanoma	0.00142	0.00318	CcSEcCtD
Alfuzosin—Flushing—Docetaxel—melanoma	0.00142	0.00318	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Temozolomide—melanoma	0.00141	0.00316	CcSEcCtD
Alfuzosin—Fatigue—Temozolomide—melanoma	0.00141	0.00316	CcSEcCtD
Alfuzosin—Pain—Temozolomide—melanoma	0.00139	0.00313	CcSEcCtD
Alfuzosin—Constipation—Temozolomide—melanoma	0.00139	0.00313	CcSEcCtD
Alfuzosin—Feeling abnormal—Carmustine—melanoma	0.00139	0.00312	CcSEcCtD
Alfuzosin—Asthenia—Bleomycin—melanoma	0.00139	0.00312	CcSEcCtD
Alfuzosin—Angiopathy—Docetaxel—melanoma	0.00139	0.00311	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Carmustine—melanoma	0.00138	0.0031	CcSEcCtD
Alfuzosin—Mediastinal disorder—Docetaxel—melanoma	0.00138	0.00309	CcSEcCtD
Alfuzosin—Pruritus—Bleomycin—melanoma	0.00137	0.00307	CcSEcCtD
Alfuzosin—Feeling abnormal—Temozolomide—melanoma	0.00134	0.00302	CcSEcCtD
Alfuzosin—Mental disorder—Docetaxel—melanoma	0.00134	0.00301	CcSEcCtD
Alfuzosin—Abdominal pain—Carmustine—melanoma	0.00133	0.003	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Temozolomide—melanoma	0.00133	0.003	CcSEcCtD
Alfuzosin—Urticaria—Temozolomide—melanoma	0.0013	0.00291	CcSEcCtD
Alfuzosin—Asthenia—Dactinomycin—melanoma	0.00129	0.00291	CcSEcCtD
Alfuzosin—Abdominal pain—Temozolomide—melanoma	0.00129	0.0029	CcSEcCtD
Alfuzosin—Back pain—Docetaxel—melanoma	0.00129	0.00289	CcSEcCtD
Alfuzosin—Diarrhoea—Dactinomycin—melanoma	0.00123	0.00277	CcSEcCtD
Alfuzosin—Vomiting—Bleomycin—melanoma	0.00123	0.00276	CcSEcCtD
Alfuzosin—Rash—Bleomycin—melanoma	0.00122	0.00274	CcSEcCtD
Alfuzosin—Dermatitis—Bleomycin—melanoma	0.00122	0.00274	CcSEcCtD
Alfuzosin—Asthenia—Carmustine—melanoma	0.00121	0.00272	CcSEcCtD
Alfuzosin—Syncope—Docetaxel—melanoma	0.00119	0.00268	CcSEcCtD
Alfuzosin—Palpitations—Docetaxel—melanoma	0.00117	0.00264	CcSEcCtD
Alfuzosin—Asthenia—Temozolomide—melanoma	0.00117	0.00263	CcSEcCtD
Alfuzosin—Loss of consciousness—Docetaxel—melanoma	0.00117	0.00262	CcSEcCtD
Alfuzosin—Diarrhoea—Carmustine—melanoma	0.00115	0.00259	CcSEcCtD
Alfuzosin—Pruritus—Temozolomide—melanoma	0.00115	0.00259	CcSEcCtD
Alfuzosin—Nausea—Bleomycin—melanoma	0.00115	0.00258	CcSEcCtD
Alfuzosin—Vomiting—Dactinomycin—melanoma	0.00115	0.00258	CcSEcCtD
Alfuzosin—Rash—Dactinomycin—melanoma	0.00114	0.00255	CcSEcCtD
Alfuzosin—Arthralgia—Docetaxel—melanoma	0.00113	0.00254	CcSEcCtD
Alfuzosin—Chest pain—Docetaxel—melanoma	0.00113	0.00254	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00112	0.00252	CcSEcCtD
Alfuzosin—Dizziness—Carmustine—melanoma	0.00112	0.00251	CcSEcCtD
Alfuzosin—Diarrhoea—Temozolomide—melanoma	0.00112	0.00251	CcSEcCtD
Alfuzosin—Dry mouth—Docetaxel—melanoma	0.00111	0.00249	CcSEcCtD
Alfuzosin—Oedema—Docetaxel—melanoma	0.00108	0.00244	CcSEcCtD
Alfuzosin—Dizziness—Temozolomide—melanoma	0.00108	0.00242	CcSEcCtD
Alfuzosin—Infection—Docetaxel—melanoma	0.00108	0.00242	CcSEcCtD
Alfuzosin—Vomiting—Carmustine—melanoma	0.00107	0.00241	CcSEcCtD
Alfuzosin—Nausea—Dactinomycin—melanoma	0.00107	0.00241	CcSEcCtD
Alfuzosin—Shock—Docetaxel—melanoma	0.00107	0.0024	CcSEcCtD
Alfuzosin—Rash—Carmustine—melanoma	0.00106	0.00239	CcSEcCtD
Alfuzosin—Nervous system disorder—Docetaxel—melanoma	0.00106	0.00239	CcSEcCtD
Alfuzosin—Dermatitis—Carmustine—melanoma	0.00106	0.00239	CcSEcCtD
Alfuzosin—Thrombocytopenia—Docetaxel—melanoma	0.00106	0.00239	CcSEcCtD
Alfuzosin—Tachycardia—Docetaxel—melanoma	0.00106	0.00238	CcSEcCtD
Alfuzosin—Headache—Carmustine—melanoma	0.00106	0.00238	CcSEcCtD
Alfuzosin—Skin disorder—Docetaxel—melanoma	0.00105	0.00237	CcSEcCtD
Alfuzosin—Vomiting—Temozolomide—melanoma	0.00104	0.00233	CcSEcCtD
Alfuzosin—Rash—Temozolomide—melanoma	0.00103	0.00231	CcSEcCtD
Alfuzosin—Dermatitis—Temozolomide—melanoma	0.00103	0.00231	CcSEcCtD
Alfuzosin—Headache—Temozolomide—melanoma	0.00102	0.0023	CcSEcCtD
Alfuzosin—Hypotension—Docetaxel—melanoma	0.00101	0.00228	CcSEcCtD
Alfuzosin—Nausea—Carmustine—melanoma	0.001	0.00225	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Docetaxel—melanoma	0.000988	0.00222	CcSEcCtD
Alfuzosin—Nausea—Temozolomide—melanoma	0.000969	0.00218	CcSEcCtD
Alfuzosin—Somnolence—Docetaxel—melanoma	0.000964	0.00217	CcSEcCtD
Alfuzosin—Dyspepsia—Docetaxel—melanoma	0.000955	0.00215	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Docetaxel—melanoma	0.000936	0.0021	CcSEcCtD
Alfuzosin—Fatigue—Docetaxel—melanoma	0.000935	0.0021	CcSEcCtD
Alfuzosin—Constipation—Docetaxel—melanoma	0.000927	0.00208	CcSEcCtD
Alfuzosin—Pain—Docetaxel—melanoma	0.000927	0.00208	CcSEcCtD
Alfuzosin—Feeling abnormal—Docetaxel—melanoma	0.000894	0.00201	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Docetaxel—melanoma	0.000887	0.00199	CcSEcCtD
Alfuzosin—Abdominal pain—Docetaxel—melanoma	0.000857	0.00193	CcSEcCtD
Alfuzosin—Asthenia—Docetaxel—melanoma	0.000778	0.00175	CcSEcCtD
Alfuzosin—Pruritus—Docetaxel—melanoma	0.000767	0.00172	CcSEcCtD
Alfuzosin—Diarrhoea—Docetaxel—melanoma	0.000742	0.00167	CcSEcCtD
Alfuzosin—Dizziness—Docetaxel—melanoma	0.000717	0.00161	CcSEcCtD
Alfuzosin—Vomiting—Docetaxel—melanoma	0.00069	0.00155	CcSEcCtD
Alfuzosin—Rash—Docetaxel—melanoma	0.000684	0.00154	CcSEcCtD
Alfuzosin—Dermatitis—Docetaxel—melanoma	0.000683	0.00154	CcSEcCtD
Alfuzosin—Headache—Docetaxel—melanoma	0.000679	0.00153	CcSEcCtD
Alfuzosin—Nausea—Docetaxel—melanoma	0.000644	0.00145	CcSEcCtD
Alfuzosin—ADRA1A—Signaling Pathways—HDAC2—melanoma	5.84e-05	0.000264	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FOXO4—melanoma	5.84e-05	0.000264	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—E2F1—melanoma	5.81e-05	0.000262	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CB—melanoma	5.78e-05	0.000261	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—GNAQ—melanoma	5.77e-05	0.000261	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PDGFRA—melanoma	5.75e-05	0.00026	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PRKCA—melanoma	5.69e-05	0.000257	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ITGB3—melanoma	5.69e-05	0.000257	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SPP1—melanoma	5.58e-05	0.000252	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAP2K2—melanoma	5.56e-05	0.000251	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CG—melanoma	5.56e-05	0.000251	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCL8—melanoma	5.55e-05	0.000251	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SOCS1—melanoma	5.55e-05	0.000251	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—MAP2K1—melanoma	5.54e-05	0.00025	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—S100B—melanoma	5.54e-05	0.00025	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CD—melanoma	5.5e-05	0.000249	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SYK—melanoma	5.43e-05	0.000245	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CD—melanoma	5.38e-05	0.000243	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PHGDH—melanoma	5.36e-05	0.000242	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—LUM—melanoma	5.36e-05	0.000242	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ITGAV—melanoma	5.33e-05	0.000241	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AKT3—melanoma	5.33e-05	0.000241	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NGFR—melanoma	5.33e-05	0.000241	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL2—melanoma	5.31e-05	0.00024	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ERBB4—melanoma	5.3e-05	0.000239	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TERT—melanoma	5.29e-05	0.000239	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CB—melanoma	5.28e-05	0.000239	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RAC1—melanoma	5.27e-05	0.000238	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HPSE—melanoma	5.26e-05	0.000238	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN2B—melanoma	5.25e-05	0.000237	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CUBN—melanoma	5.16e-05	0.000233	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CD86—melanoma	5.08e-05	0.00023	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCL8—melanoma	5.08e-05	0.000229	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HIF1A—melanoma	5.06e-05	0.000229	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EDN1—melanoma	5.04e-05	0.000228	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SDHD—melanoma	4.99e-05	0.000225	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—BSG—melanoma	4.99e-05	0.000225	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CSPG4—melanoma	4.99e-05	0.000225	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SOCS1—melanoma	4.93e-05	0.000223	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CSF2—melanoma	4.92e-05	0.000223	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FGF1—melanoma	4.92e-05	0.000223	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—MAP2K1—melanoma	4.92e-05	0.000222	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—S100B—melanoma	4.92e-05	0.000222	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CD—melanoma	4.89e-05	0.000221	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—IL2—melanoma	4.85e-05	0.000219	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KDR—melanoma	4.84e-05	0.000219	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GPAM—melanoma	4.83e-05	0.000218	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—E2F1—melanoma	4.82e-05	0.000218	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CB—melanoma	4.8e-05	0.000217	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PDGFRA—melanoma	4.77e-05	0.000216	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ITGB3—melanoma	4.72e-05	0.000213	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PRKCA—melanoma	4.72e-05	0.000213	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ERBB4—melanoma	4.71e-05	0.000213	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CB—melanoma	4.69e-05	0.000212	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN2B—melanoma	4.66e-05	0.000211	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FN1—melanoma	4.66e-05	0.00021	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SPP1—melanoma	4.63e-05	0.000209	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAP2K2—melanoma	4.62e-05	0.000209	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCL8—melanoma	4.61e-05	0.000208	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NOTCH1—melanoma	4.56e-05	0.000206	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CD86—melanoma	4.51e-05	0.000204	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCL8—melanoma	4.51e-05	0.000204	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EDN1—melanoma	4.48e-05	0.000202	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CD80—melanoma	4.46e-05	0.000202	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KIT—melanoma	4.46e-05	0.000201	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CG—melanoma	4.46e-05	0.000201	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—APC—melanoma	4.46e-05	0.000201	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—NRAS—melanoma	4.46e-05	0.000201	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL2—melanoma	4.41e-05	0.000199	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EGF—melanoma	4.4e-05	0.000199	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TERT—melanoma	4.39e-05	0.000198	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RAC1—melanoma	4.38e-05	0.000198	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FGF1—melanoma	4.37e-05	0.000198	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CSF2—melanoma	4.37e-05	0.000198	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—IL2—melanoma	4.31e-05	0.000195	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—E2F1—melanoma	4.28e-05	0.000193	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—MAPK3—melanoma	4.27e-05	0.000193	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CB—melanoma	4.26e-05	0.000193	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PDGFRA—melanoma	4.24e-05	0.000191	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HIF1A—melanoma	4.2e-05	0.00019	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ITGB3—melanoma	4.19e-05	0.00019	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PRKCA—melanoma	4.19e-05	0.00019	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—BRAF—melanoma	4.19e-05	0.000189	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SPP1—melanoma	4.11e-05	0.000186	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PLA2G6—melanoma	4.11e-05	0.000186	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAP2K2—melanoma	4.1e-05	0.000185	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCL8—melanoma	4.09e-05	0.000185	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IGF1—melanoma	4.08e-05	0.000184	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—MAPK1—melanoma	4.06e-05	0.000184	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—EGFR—melanoma	4.06e-05	0.000183	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KDR—melanoma	4.01e-05	0.000181	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAP2K1—melanoma	3.94e-05	0.000178	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CD—melanoma	3.92e-05	0.000177	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL2—melanoma	3.91e-05	0.000177	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TERT—melanoma	3.9e-05	0.000176	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RAC1—melanoma	3.89e-05	0.000176	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PIK3CA—melanoma	3.88e-05	0.000175	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FN1—melanoma	3.86e-05	0.000175	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—KRAS—melanoma	3.84e-05	0.000173	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NOTCH1—melanoma	3.78e-05	0.000171	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FGF2—melanoma	3.75e-05	0.00017	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HIF1A—melanoma	3.73e-05	0.000169	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CD80—melanoma	3.7e-05	0.000167	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KIT—melanoma	3.7e-05	0.000167	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CG—melanoma	3.7e-05	0.000167	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—APC—melanoma	3.7e-05	0.000167	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—NRAS—melanoma	3.7e-05	0.000167	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—VCAN—melanoma	3.69e-05	0.000167	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EGF—melanoma	3.66e-05	0.000165	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KDR—melanoma	3.57e-05	0.000161	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—MAPK3—melanoma	3.54e-05	0.00016	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PIK3CA—melanoma	3.52e-05	0.000159	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MDM2—melanoma	3.51e-05	0.000159	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—BRAF—melanoma	3.48e-05	0.000157	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ERBB2—melanoma	3.46e-05	0.000156	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FN1—melanoma	3.43e-05	0.000155	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CB—melanoma	3.41e-05	0.000154	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IGF1—melanoma	3.39e-05	0.000153	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—MAPK1—melanoma	3.37e-05	0.000152	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—EGFR—melanoma	3.37e-05	0.000152	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NOTCH1—melanoma	3.36e-05	0.000152	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CD80—melanoma	3.29e-05	0.000149	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CG—melanoma	3.28e-05	0.000148	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—APC—melanoma	3.28e-05	0.000148	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KIT—melanoma	3.28e-05	0.000148	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—NRAS—melanoma	3.28e-05	0.000148	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCL8—melanoma	3.28e-05	0.000148	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAP2K1—melanoma	3.27e-05	0.000148	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HRAS—melanoma	3.26e-05	0.000147	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CD—melanoma	3.25e-05	0.000147	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EGF—melanoma	3.25e-05	0.000147	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PIK3CA—melanoma	3.22e-05	0.000146	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1B—melanoma	3.2e-05	0.000145	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—KRAS—melanoma	3.18e-05	0.000144	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—AKT1—melanoma	3.17e-05	0.000143	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—MAPK3—melanoma	3.15e-05	0.000142	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CASP3—melanoma	3.14e-05	0.000142	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL2—melanoma	3.14e-05	0.000142	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL6—melanoma	3.12e-05	0.000141	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FGF2—melanoma	3.11e-05	0.000141	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP17A1—melanoma	3.11e-05	0.000141	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—BRAF—melanoma	3.09e-05	0.00014	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CCND1—melanoma	3.06e-05	0.000138	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CTNNB1—melanoma	3.03e-05	0.000137	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IGF1—melanoma	3.01e-05	0.000136	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—MAPK1—melanoma	2.99e-05	0.000135	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—EGFR—melanoma	2.99e-05	0.000135	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MMP9—melanoma	2.97e-05	0.000134	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CDKN1A—melanoma	2.96e-05	0.000134	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PTEN—melanoma	2.95e-05	0.000133	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GNA11—melanoma	2.94e-05	0.000133	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NFKB1—melanoma	2.94e-05	0.000133	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	2.92e-05	0.000132	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MDM2—melanoma	2.91e-05	0.000132	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAP2K1—melanoma	2.91e-05	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CD—melanoma	2.89e-05	0.000131	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—AKT1—melanoma	2.88e-05	0.00013	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—FASN—melanoma	2.88e-05	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ERBB2—melanoma	2.87e-05	0.00013	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	2.86e-05	0.000129	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CB—melanoma	2.83e-05	0.000128	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—SLC5A5—melanoma	2.83e-05	0.000128	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—KRAS—melanoma	2.83e-05	0.000128	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FGF2—melanoma	2.77e-05	0.000125	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CD44—melanoma	2.73e-05	0.000124	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GNAQ—melanoma	2.73e-05	0.000124	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCL8—melanoma	2.72e-05	0.000123	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HRAS—melanoma	2.71e-05	0.000122	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—VEGFA—melanoma	2.66e-05	0.00012	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1B—melanoma	2.66e-05	0.00012	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—STAT3—melanoma	2.64e-05	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NRAS—melanoma	2.63e-05	0.000119	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—AKT1—melanoma	2.63e-05	0.000119	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP1B1—melanoma	2.62e-05	0.000118	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CASP3—melanoma	2.61e-05	0.000118	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL2—melanoma	2.6e-05	0.000118	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	2.6e-05	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL6—melanoma	2.59e-05	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MDM2—melanoma	2.59e-05	0.000117	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ERBB2—melanoma	2.55e-05	0.000115	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CCND1—melanoma	2.54e-05	0.000115	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK3—melanoma	2.52e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CB—melanoma	2.52e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CTNNB1—melanoma	2.51e-05	0.000114	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MMP9—melanoma	2.46e-05	0.000111	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CDKN1A—melanoma	2.45e-05	0.000111	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MYC—melanoma	2.45e-05	0.000111	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PTEN—melanoma	2.45e-05	0.000111	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NFKB1—melanoma	2.44e-05	0.00011	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCL8—melanoma	2.42e-05	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HRAS—melanoma	2.4e-05	0.000109	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MAPK1—melanoma	2.4e-05	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EGFR—melanoma	2.4e-05	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—AKT1—melanoma	2.39e-05	0.000108	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1B—melanoma	2.36e-05	0.000107	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—AKT1—melanoma	2.34e-05	0.000106	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CASP3—melanoma	2.32e-05	0.000105	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL2—melanoma	2.31e-05	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL6—melanoma	2.3e-05	0.000104	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KRAS—melanoma	2.27e-05	0.000102	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CCND1—melanoma	2.25e-05	0.000102	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CTNNB1—melanoma	2.23e-05	0.000101	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—VEGFA—melanoma	2.21e-05	0.0001	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—STAT3—melanoma	2.19e-05	9.9e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MMP9—melanoma	2.19e-05	9.89e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NRAS—melanoma	2.18e-05	9.87e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CDKN1A—melanoma	2.18e-05	9.85e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PTEN—melanoma	2.18e-05	9.83e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NFKB1—melanoma	2.16e-05	9.78e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ABCB1—melanoma	2.16e-05	9.75e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—AKT1—melanoma	2.12e-05	9.59e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK3—melanoma	2.09e-05	9.46e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PIK3CA—melanoma	2.08e-05	9.41e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MYC—melanoma	2.03e-05	9.2e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TP53—melanoma	2.01e-05	9.1e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MAPK1—melanoma	1.99e-05	9e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EGFR—melanoma	1.99e-05	9e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PRKCA—melanoma	1.99e-05	8.97e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ERCC2—melanoma	1.97e-05	8.9e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—VEGFA—melanoma	1.96e-05	8.88e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—STAT3—melanoma	1.95e-05	8.79e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NRAS—melanoma	1.94e-05	8.77e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HRAS—melanoma	1.93e-05	8.7e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KRAS—melanoma	1.88e-05	8.5e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK3—melanoma	1.86e-05	8.4e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6—melanoma	1.84e-05	8.33e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MYC—melanoma	1.81e-05	8.17e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MAPK1—melanoma	1.77e-05	7.99e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EGFR—melanoma	1.77e-05	7.99e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PIK3CA—melanoma	1.73e-05	7.81e-05	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—AKT1—melanoma	1.7e-05	7.69e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TP53—melanoma	1.67e-05	7.55e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KRAS—melanoma	1.67e-05	7.55e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HRAS—melanoma	1.6e-05	7.22e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CG—melanoma	1.56e-05	7.03e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PIK3CA—melanoma	1.53e-05	6.94e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6—melanoma	1.53e-05	6.91e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PPARG—melanoma	1.5e-05	6.78e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TP53—melanoma	1.48e-05	6.71e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HRAS—melanoma	1.42e-05	6.42e-05	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—AKT1—melanoma	1.41e-05	6.38e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CD—melanoma	1.37e-05	6.18e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6—melanoma	1.36e-05	6.14e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALB—melanoma	1.35e-05	6.1e-05	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—AKT1—melanoma	1.25e-05	5.67e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CB—melanoma	1.19e-05	5.39e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PTGS2—melanoma	1.18e-05	5.34e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PTEN—melanoma	1.03e-05	4.65e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—PIK3CA—melanoma	7.26e-06	3.28e-05	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—AKT1—melanoma	5.93e-06	2.68e-05	CbGpPWpGaD
